Anne Wojcicki, the CEO and a co-founder of 23andMe, tells Nature's Soapbox Science blog that her company is moving toward working with pharmaceutical companies on phase 4, post-marketing studies. The company's database contains data from about 150,000 customers, the blog adds. "We definitely want to connect more and more with pharma partners to leverage the platform we've created," Wojcicki says. "The example I gave — phase 4 studies, following patients over time, understanding how they are using therapies, collecting quality of life data — it's something that we're perfectly set up to do." She adds that adding a genetic aspect to phase 4 studies could help identify both responders and adverse event subgroups.
The Database Connection
Sep 26, 2012